GPCR Archives

News and Trends 28 Apr 2022

OMass Therapeutics Takes on ‘Undruggable’ Proteins with €90M Series B

The UK firm OMass Therapeutics has unveiled a €90M (£75.5M) Series B financing to bankroll the development of small molecules against so-called ‘undruggable’ targets, including one that sank Quench Bio last year. In 2020, Quench Bio captured the imagination of investors with the US firm’s ambition to develop a new class of anti-inflammatory drugs. The […]

April 28, 2022 - 3 minutesmins - By Jonathan Smith

News and Trends 7 May 2019

Belgian Biotech Raises €30M Series A to Unlock Undruggable Targets

Confo Therapeutics has raised €30M in a Series A round that will take its unique technology to find drugs for historically undruggable targets to clinical trials. The fundraising was led by the VCs BioGeneration Ventures and Wellington Partners, and joined by several other private and public investors. With the money, Confo Therapeutics aims to […]

May 7, 2019 - 3 minutesmins - By Clara Rodríguez Fernández

Nobel Prize in Chemistry 2017 Richard Henderson Heptares Therapeutics

News and Trends 5 Oct 2017

British Biotech Founder Receives the Nobel Prize in Chemistry 2017

Richard Henderson, awarded the Nobel Prize in Chemistry 2017, founded Heptares Therapeutics to apply his Nobel-winning technology to discover new medicines. This year’s Nobel Prize in Chemistry has been awarded to Jacques Dubochet, Joachim Frank and Richard Henderson for the development of cryo-electron microscopy. This technology, now widely used in structural biology labs, is considered a stepping […]

October 5, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 2 Oct 2017

Meet the Young CEO of a PCR Workflow Automation Company

He is a young entrepreneur with a fast growing company. His software for the automation of PCR results interpretation in research laboratories has had a rocket start. Here’s his story! “I was looking for an internship for my bachelor’s degree in computer science…” His story starts like so many others, but unlike most it took […]

October 2, 2017 - 7 minutesmins - By External Contributor

News and Trends 26 Sep 2017

Belgian Biotech Teams Up With Lundbeck to Collaborate on Drug Discovery

Confo and Lundbeck have joined forces to push through drug discovery against a tough-to-target protein using Confo’s special technology. Confo Therapeutics develops small antibody fragments, ‘Confobodies’, that stabilize G-protein coupled receptors (GPCRs). Although Lundbeck has the exclusive license to commercialize compounds from the collaboration, Confo would receive up to €5M in technology fees, plus milestone payments and royalties depending on […]

September 26, 2017 - 2 minutesmins - By Alex Dale

Allergan Heptares Therapeutics alzheimers

News and Trends 1 Sep 2017

Allergan Takes to the Clinic a New Alzheimer’s Drug from a €3Bn Deal

Allergan’s partner Heptares Therapeutics has dosed the first patient with a GPCR drug to treat major symptoms of Alzheimer’s disease. A year ago, Allergan signed a massive deal of up to €3Bn with Heptares Therapeutics for the development of drugs that target G-protein-coupled receptors (GPCRs), a protein superfamily that currently comprises the target of around […]

September 1, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

Interview 17 Jul 2017

Pinning Down Elusive Targets: Interviewing the Co-Founder & CSO of Heptares

Heptares is expanding into a range of indications with its GPCR platform. I caught up with CSO & co-founder Fiona Marshall to hear more about the strategy. Fiona Marshall has always worked on G-protein coupled receptors, or GPCRs for short. These entities are key to many eukaryotic signaling pathways, and because of their prevalence, they’re […]

July 17, 2017 - 6 minutesmins - By Evelyn Warner

News and Trends 19 May 2017

MorphoSys’ First Lanthipeptide Completes Phase I Successfully

UPDATE (19/05/2017): MorphoSys has announced the completion of the Phase I study with MOR107, which has proved safe and showed dose-dependent pharmacokinetics. The drug, an agonist of the angiotensin II receptor type 2 (AT2-R), comes from the Dutch Lanthio Pharma and is the first lanthipeptide in MorphoSys’ pipeline. Originally published 21/02/2017 Lanthio Pharma has initiated a […]

May 19, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 18 May 2017

Heptares receives €4.5M Milestone for New Migraine Drug Candidate

The UK biotech attacking notoriously evasive GPCRs has discovered a small molecule that could be used to treat migraine headaches. Heptares, owned by Sosei and based just outside London, will take home €4.5M ($5M) from Teva for discovering a drug candidate for migraine treatment. The small molecule is an calcitonin gene-related peptide (CGRP) agonist that could relieve patients […]

May 18, 2017 - 1 minutemin - By Evelyn Warner

News and Trends 27 Apr 2017

Heptares Finds New GPCR Target to Treat Pain, Cancer and Inflammation

Heptares Therapeutics has published the detailed structure and mechanism of action of a difficult-to-target GPCR protein with great therapeutic prospects. Heptares Therapeutics has published today in Nature new insights into the mechanism of action of antagonists of the protease-activated receptor 2 (PAR2), a molecule involved in metabolism and inflammatory responses. The study is part of […]

April 27, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 1 Feb 2017

Young Belgian Biotech will tackle Fibrosis with a New Grant

Confo Therapeutics has received a €1.6M grant to support the discovery of drugs against fibrosis, one of the most deadly conditions in Western countries. Confo Therapeutics is a young biotech in Brussels developing a unique technology to target historically undruggable G protein-coupled receptors (GPCRs). The company just announced it received a €1.6M grant from Flanders Innovation & […]

February 1, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 31 Jan 2017

New British Biotech-Academia Alliance takes on Cardiovascular Disease

Heptares Therapeutics and the University of Cambridge have partnered to investigate a novel target for cardiovascular diseases. Heptares Therapeutics, based in London, develops drugs against historically undruggable G protein-coupled receptors (GPCRs). The company has now announced a new research collaboration with the University of Cambridge focusing on a specific GPCR, the apelin receptor. Heptares will support a […]

January 31, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

Knowledge hub

Categories

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Approaches

Therapeutic areas

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

GPCR

OMass Therapeutics Takes on ‘Undruggable’ Proteins with €90M Series B

Belgian Biotech Raises €30M Series A to Unlock Undruggable Targets

British Biotech Founder Receives the Nobel Prize in Chemistry 2017

Meet the Young CEO of a PCR Workflow Automation Company

Belgian Biotech Teams Up With Lundbeck to Collaborate on Drug Discovery

Allergan Takes to the Clinic a New Alzheimer’s Drug from a €3Bn Deal

Pinning Down Elusive Targets: Interviewing the Co-Founder & CSO of Heptares

MorphoSys’ First Lanthipeptide Completes Phase I Successfully

Heptares receives €4.5M Milestone for New Migraine Drug Candidate

Heptares Finds New GPCR Target to Treat Pain, Cancer and Inflammation

Young Belgian Biotech will tackle Fibrosis with a New Grant

New British Biotech-Academia Alliance takes on Cardiovascular Disease

Subscribe to our newsletter to get the latest biotech news!

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!